← Back to All US Stocks

Opko Health, Inc.. (OPK) Fundamental Analysis & AI Grade 2026

OPK Nasdaq Pharmaceutical Preparations DE CIK: 0000944809
Updated This Month • Analysis: May 6, 2026 • SEC Data: 2026-03-31
Combined AI Grade
C
74% Confidence
STRONG AGREEMENT
C
78% Conf
C
70% Conf

📊 OPK Key Takeaways

Revenue: $124.2M
Net Margin: -44.2%
Free Cash Flow: $-21.1M
Current Ratio: 3.61x
Debt/Equity: 0.29x
EPS: $-0.07
AI Grade: C with 78% confidence
Opko Health, Inc.. (OPK) receives a C fundamental grade with 74% confidence from our AI analysis based on SEC 10-K filings. With revenue of $124.2M, net profit margin of -44.2%, and return on equity (ROE) of -4.6%, Opko Health, Inc.. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete OPK stock analysis for 2026.

Is Opko Health, Inc.. (OPK) a Good Investment?

Claude

OPKO Health is operationally distressed with a -41% operating margin, declining revenue (-14.9% YoY), and negative free cash flow of -$21.1M despite maintaining a solid balance sheet. The company is consuming cash reserves to fund operations and lacks profitability visibility, presenting significant fundamental risks.

ChatGPT

Fundamentals have deteriorated with double-digit revenue decline, widening losses, and deeply negative operating and free cash flow. While liquidity and leverage are favorable, the lack of interest coverage and unclear path to profitability make the risk/reward unattractive until cash burn abates and revenues stabilize.

Opko Health, Inc.. Key Strengths (OPK)

Claude
  • + Strong balance sheet with $1.2B stockholders' equity
  • + Excellent liquidity ratios (3.61x current, 3.17x quick) providing operational cushion
  • + Moderate leverage with 0.29x debt-to-equity ratio
  • + Reasonable gross margin of 36.8% suggests product viability
ChatGPT
  • + Strong liquidity (current/quick ~4x/3.5x)
  • + Moderate leverage with sizable cash balance
  • + Decent gross margin providing operating leverage potential

OPK Stock Risks: Opko Health, Inc.. Investment Risks

Claude
  • ! Severe operating losses of -$51.0M on declining $124.2M revenue base
  • ! Negative operating cash flow (-$19.3M) and free cash flow (-$21.1M) indicate unsustainable cash burn
  • ! Declining revenue trajectory (-14.9% YoY) with no apparent stabilization
  • ! Net losses of -$54.8M consuming balance sheet reserves; long-term sustainability questionable
ChatGPT
  • ! Sustained negative OCF and FCF indicating cash burn
  • ! Revenue down 14.9% YoY, weakening top-line
  • ! No interest coverage; potential dilution or refinancing risk if burn persists

Key Metrics to Watch

Claude
  • * Operating cash flow trend - must return to positive
  • * Revenue stabilization and growth trajectory
  • * Operating margin recovery path and timeline to profitability
ChatGPT
  • * Operating cash flow (TTM trend)
  • * Revenue growth (YoY)

Opko Health, Inc.. (OPK) Financial Metrics & Key Ratios

Revenue
$124.2M
Net Income
$-54.8M
EPS (Diluted)
$-0.07
Free Cash Flow
$-21.1M
Total Assets
$1.9B
Cash Position
$331.9M

💡 AI Analyst Insight

Strong liquidity with a 3.61x current ratio provides a solid financial cushion.

OPK Profit Margin, ROE & Profitability Analysis

Gross Margin 36.8%
Operating Margin -41.1%
Net Margin -44.2%
ROE -4.6%
ROA -3.0%
FCF Margin -17.0%

OPK vs Healthcare Sector: How Opko Health, Inc.. Compares

How Opko Health, Inc.. compares to Healthcare sector averages

Net Margin
OPK -44.2%
vs
Sector Avg 12.0%
OPK Sector
ROE
OPK -4.6%
vs
Sector Avg 15.0%
OPK Sector
Current Ratio
OPK 3.6x
vs
Sector Avg 2.0x
OPK Sector
Debt/Equity
OPK 0.3x
vs
Sector Avg 0.6x
OPK Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Opko Health, Inc.. Stock Overvalued? OPK Valuation Analysis 2026

Based on fundamental analysis, Opko Health, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-4.6%
Sector avg: 15%
Net Profit Margin
-44.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.29x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Opko Health, Inc.. Balance Sheet: OPK Debt, Cash & Liquidity

Current Ratio
3.61x
Quick Ratio
3.17x
Debt/Equity
0.29x
Debt/Assets
35.1%
Interest Coverage
N/A
Long-term Debt
$345.7M

OPK Revenue & Earnings Growth: 5-Year Financial Trend

OPK 5-year financial data: Year 2021: Revenue $1.8B, Net Income -$314.9M, EPS $-0.53. Year 2022: Revenue $1.8B, Net Income $30.6M, EPS $0.05. Year 2023: Revenue $1.8B, Net Income -$30.1M, EPS N/A. Year 2024: Revenue $1.0B, Net Income -$328.4M, EPS $-0.12. Year 2025: Revenue $863.5M, Net Income -$188.9M, EPS $-0.25.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Opko Health, Inc..'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-0.25 indicates the company is currently unprofitable.

OPK Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-17.0%
Free cash flow / Revenue

OPK Quarterly Earnings & Performance

Quarterly financial performance data for Opko Health, Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $124.2M -$54.8M $-0.07
Q3 2025 $151.7M $21.6M $0.03
Q2 2025 $156.8M -$10.3M $-0.01
Q1 2025 $150.0M -$67.6M N/A
Q3 2024 $173.6M $24.9M $0.03
Q2 2024 $182.2M -$10.3M N/A
Q1 2024 $173.7M -$18.3M N/A
Q3 2023 $178.6M -$84.5M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Opko Health, Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$19.3M
Cash generated from operations
Stock Buybacks
$4.8M
Shares repurchased (TTM)
Capital Expenditures
$1.8M
Investment in assets
Dividends Paid
$4.7M
Returned to shareholders

OPK SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Opko Health, Inc.. (CIK: 0000944809)

📋 Recent SEC Filings

Date Form Document Action
Apr 30, 2026 DEF 14A opk-20260430.htm View →
Apr 28, 2026 10-Q opk-20260331.htm View →
Apr 28, 2026 8-K opk-20260428.htm View →
Mar 20, 2026 4 xslF345X06/ownership.xml View →
Mar 20, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about OPK

What is the AI rating for OPK?

Opko Health, Inc.. (OPK) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are OPK's key strengths?

Claude: Strong balance sheet with $1.2B stockholders' equity. Excellent liquidity ratios (3.61x current, 3.17x quick) providing operational cushion. ChatGPT: Strong liquidity (current/quick ~4x/3.5x). Moderate leverage with sizable cash balance.

What are the risks of investing in OPK?

Claude: Severe operating losses of -$51.0M on declining $124.2M revenue base. Negative operating cash flow (-$19.3M) and free cash flow (-$21.1M) indicate unsustainable cash burn. ChatGPT: Sustained negative OCF and FCF indicating cash burn. Revenue down 14.9% YoY, weakening top-line.

What is OPK's revenue and growth?

Opko Health, Inc.. reported revenue of $124.2M.

Does OPK pay dividends?

Opko Health, Inc.. pays dividends, with $4.7M distributed to shareholders in the trailing twelve months.

Where can I find OPK SEC filings?

Official SEC filings for Opko Health, Inc.. (CIK: 0000944809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OPK's EPS?

Opko Health, Inc.. has a diluted EPS of $-0.07.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is OPK's fundamental grade?

Based on our AI fundamental analysis in May 2026, Opko Health, Inc.. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is OPK stock overvalued or undervalued?

Valuation metrics for OPK: ROE of -4.6% (sector avg: 15%), net margin of -44.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is OPK's AI grade for 2026?

Our dual AI analysis gives Opko Health, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OPK's free cash flow?

Opko Health, Inc..'s operating cash flow is $-19.3M, with capital expenditures of $1.8M. FCF margin is -17.0%.

How does OPK compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -44.2% (avg: 12%), ROE -4.6% (avg: 15%), current ratio 3.61 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 6, 2026 | Data as of: 2026-03-31 | Powered by Claude AI